Novartis’ Afinitor Fails in Breast Cancer Indication Study

Drug Industry Daily
A A
Novartis’ cancer drug Afinitor failed to significantly increase survival rates for patients with a rare type of advanced breast cancer, casting further doubt on the drugmaker’s efforts to expand uses of the blockbuster therapy.

To View This Article:

Login

Subscribe To Drug Industry Daily